Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 94-8862 dose-ranging study in diabetic nephropathy
NL-OMON38909Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing BAY 94-8862 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Change in urinary albumin-to-creatininine ratio. Started Sep 2013; status: active, not recruiting.
02
Drugs
finerenone
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on NL-OMON38909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38909.